BS_5YJEPPTP
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 22.568988173455978
- age_years
- 4.981
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.513
- ALLOGRAFT_REJECTION+0.499
- IL6_JAK_STAT3_SIGNALING+0.496
- INFLAMMATORY_RESPONSE+0.475
- INTERFERON_GAMMA_RESPONSE+0.456
- TNFA_SIGNALING_VIA_NFKB+0.445
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.431
- COAGULATION+0.408
- APOPTOSIS+0.392
- IL2_STAT5_SIGNALING+0.392
Top 10 suppressed
- E2F_TARGETS-0.497
- G2M_CHECKPOINT-0.435
- DNA_REPAIR-0.380
- MITOTIC_SPINDLE-0.316
- MYC_TARGETS_V2-0.274
- MYC_TARGETS_V1-0.247
- OXIDATIVE_PHOSPHORYLATION-0.161
- SPERMATOGENESIS-0.083
- WNT_BETA_CATENIN_SIGNALING+0.006
- PI3K_AKT_MTOR_SIGNALING+0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_55JW3HFM | Ganglioglioma | — | 0.956 |
| 2 | BS_52426AMF | low-grade glioma | — | 0.946 |
| 3 | BS_E4GC9EXR | Ganglioglioma | — | 0.938 |
| 4 | BS_V89HGTET | pilocytic astrocytoma | — | 0.935 |
| 5 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.935 |
| 6 | BS_24AHZ9ZW | low-grade glioma | — | 0.933 |
| 7 | BS_MF9X3PKH | low-grade glioma | — | 0.929 |
| 8 | BS_NRPG5K4K | low-grade glioma | — | 0.929 |
| 9 | BS_769BDPDB | pilocytic astrocytoma | — | 0.928 |
| 10 | SRR5088929 | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.513 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.499 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.496 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.475 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.456 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.445 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.431 | Inavolisib | — uncovered |
| COAGULATION | 0.408 | Binimetinib | — uncovered |
| APOPTOSIS | 0.392 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.392 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.391 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.381 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.366 | Inavolisib | — uncovered |
| COMPLEMENT | 0.363 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.356 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.353 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.349 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.341 | Idelalisib | — uncovered |